Vétoquinol : Solid Growth in Q2 2014: 8.8%

FIRST HALF NET INCOME UP 4.2%

LURE, France--(BUSINESS WIRE)--July 31, 2014-- 

Regulatory News:

Vétoquinol (Paris:VETO):

At its July 30, 2014 meeting, the Vétoquinol S.A. Board of Directors reviewed the Group results and approved the financial statements for the first six months of 2014.

 
EUR million                    2014 H1    2013 H1    Change 
----------------------------   --------   --------   ------ 
                       Sales    149.4                +2.7% 
  At constant exchange rates     153.8     145.5      +5.7% 
----------------------------   --------   --------   ------ 
                         EBIT     15.0       14.4 
              As a % of sales     10.0%       9.9%    +4.3% 
-----------------------------   ---------   -------   ------ 
      Net income, Group share     10.4       9.9 
              As a % of sales      6.9%       6.8%    +4.2% 
-----------------------------   ---------   -------   ------ 
 

Continued growth of reference products, up 9.9% vs. previous year

The Vétoquinol Group reported first half 2014 sales of EUR149.4 million, up 2.7% vs H1 2013. Sales growth was particularly strong in the second quarter at 8.8%.

At constant exchange rates, first half sales amounted to EUR153.8 million, up 5.7%. First half results were hit by a negative currency impact of EUR4.4 million, mainly due to the weakening of the US and Canadian dollars, Indian rupee and Brazilian real. At constant exchange rates and consolidation scope (like for like), sales increased by 2.6%. The Bioniche business acquired on April 15, 2014 achieved sales of EUR4.5 million.

Vétoquinol's reference products, the drivers of its strategy, continued to grow, up 9.9% based on reported data and up 7.1% at constant exchange rates. Reference products accounted for 46.3% of total Group sales in the first half of 2014 compared to 43.3% for the same period last year.

In the Group's strategic territories, first half sales at constant exchange rates rose by 3.3% in Europe, 6.5% in the Americas and 14.4% in Asia Pacific.

Sales of companion animal products increased by 5.6% over this period, while food producing animal products fell slightly (down 0.5%).

EBIT growth of 4.3%

First half EBIT came to EUR15.0 million, up 4.3% compared with the same period last year. This improvement reflects positive developments in the product mix, tight control of expenditure and the impact of the consolidation of Bioniche as from April 15, 2014.

Operating income amounted to EUR14.3 million including EUR0.7 million in non-recurring expenses related to the Bioniche acquisition.

Net financial income for the first half came in at EUR0.5 million, impacted by higher returns on cash investments and the inclusion of interest expenses related to the Group's two most recent acquisitions.

Net income Group share increased by 4.2% to EUR10.4 million.

Financial structure remains strong

At June 30, 2014, Group net cash on hand was EUR5.2 million. This takes into account the impact of the acquisition of the Bioniche animal health division completed on April 15, 2014. Barring acquisitions, the Group's cash balance generally sees a more substantial improvement during the second half of the year.

Group working capital at June 30, 2014 includes the impact of the Bioniche consolidation and the creation of reserve inventories in preparation for the major industrial expenditure program scheduled for the Group's main production facility during the second half of the year.

This highlights the Group's capacity to fund its growth and further evidences the solidity of its financial structure enabling it to pursue its growth strategy.

Confidence in the Group's outlook

"We continue to put our energy into developing our reference products; every half year sees a further improvement in our brands' reputation and the profitability of the Vétoquinol Group continues to grow, " Vétoquinol CEO Matthieu Frechin affirmed. "Acquiring the Bioniche Life Sciences Inc. animal health business has allowed us to accelerate our growth in the US market and gain a foothold in Australia. We are confident in our ability to achieve our EBIT growth target in terms of value".

Next update: 2014 Q3 sales, October 23, 2014 after market close

About Vétoquinol

Vétoquinol is a leading global player in the animal health sector serving both the livestock (cattle and pigs) and pet (dogs and cats) markets.

An independent pure player, Vétoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region.

Since its foundation in 1933, Vétoquinol has pursued a strategy combining innovation with geographical diversification. The Group's hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. Vétoquinol employs over 1,950 people.

Vétoquinol has been listed on NYSE Euronext Paris since 2006 (symbol: VETO).

For more information: www.vetoquinol.com.

OUR BUSINESS: ANIMALS. OUR ADVANTAGE: PEOPLE.

VETOQUINOL -- 34 rue du Chêne Sainte Anne - Magny-Vernois -- 70204 Lure Cedex -- France

www.vetoquinol.com

 
    CONTACT: VETOQUINOL 

Investor Relations

Marie-Josée AUBRY-ROTA, Tel.: +33 (0)3 84 62 59 88

[email protected]

or

KEIMA COMMUNICATION

Investor Relations and Media Relations

Emmanuel DOVERGNE, Tel.: +33 (0)1 56 43 44 63

[email protected]

 
    SOURCE: Vétoquinol 
Copyright Business Wire 2014 
 

Access Investor Kit for Vétoquinol SA

Visit http://www.companyspotlight.com/partner?cp_code=A591&isin=FR0004186856

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…